Go to the list of all blogs
published in Blogs
May 01, 2026
Lockheed Martin (LMT) Stock Drops -17% Over Past 30 Days on Earnings Miss and Delays

Lockheed Martin (LMT) Stock Drops -17% Over Past 30 Days on Earnings Miss and Delays

Key Takeaways

  • LMT stock declined approximately -17% over the past 30 days, primarily driven by a Q1 2026 earnings miss, production delays on key programs like the F-16, and negative free cash flow.
  • Over the past quarter, shares fell around -19%, erasing earlier gains amid company-specific challenges despite strong sector demand for defense products.
  • Aeronautics segment profit dropped 14% due to fixed-price contract costs and F-16 issues, weighing heavily on overall results.
  • Despite the pullback, LMT maintains a $186 billion backlog and reaffirmed full-year guidance, supported by geopolitical demand.
  • Defense sector ETFs saw prior inflows, but LMT underperformed peers like RTX due to execution risks.

Lockheed Martin (LMT): A Key Player in Aerospace and Defense Portfolios

Lockheed Martin Corporation (LMT) remains a cornerstone in the aerospace and defense space, serving as a strong single-stock proxy for ETF-style exposure to the sector. Rather than tracking an index, it offers direct access to a diversified business across four core segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The company delivers advanced technology systems to the U.S. government and international customers, with flagship programs like the F-35 Lightning II fighter jet driving much of its revenue. From what I see, this setup makes recent price action particularly telling, as setbacks in major programs like these ripple straight through to earnings and broader investor views on defense themes.

LMT Price Performance: The Last 30 Days Versus the Quarter

In the past 30 days, LMT shares dropped sharply by -16.9%, moving from around $618 to $514 in a volatile, downward-trending slide following earnings. The decline picked up speed after April 23, with several straight losing sessions amid intensified selling.

Looking at the full quarter, the stock fell -19.0%, from about $634 to $514, transitioning from early range-bound trading to a pronounced downtrend that lagged major indices.

Key Drivers Behind LMT's 30-Day Decline

The main trigger for LMT's 30-day drop was its Q1 2026 earnings release on April 23, which fell short of expectations. Earnings per share (EPS) landed at $6.44, missing forecasts, while sales hit $18.0 billion against the anticipated $18.24 billion. Free cash flow (FCF) turned negative at -$291 million, hit by working capital shifts and squeezed margins. Production holdups on the F-16 fighter and C-130 Hercules aircraft, plus elevated costs from fixed-price contracts, hit the Aeronautics segment—its biggest revenue driver—leading to a 14% profit decline. The stock fell 4.7% that day and kept sliding over eight sessions, even as munitions demand stayed solid. In my view, the market soured on execution risks, overshadowing the solid $186 billion backlog.

I also checked this using Tickeron’s AI Screener to gauge how LMT stacks up against other defense names on fundamentals and trends.

What Shaped LMT's Performance Over the Quarter

Over the quarter, LMT's slide marked a reversal from earlier 2026 gains, as operational challenges piled up. The broader defense sector rode tailwinds from geopolitical tensions and ETF inflows into aerospace, but LMT grappled with supply chain strains and program delays. The Q1 miss poured fuel on these issues, with negative FCF and segment margin pressure denting confidence. Steady U.S. defense budgets lifted peers, yet LMT's exposure to fixed-price contracts and F-16/C-130 setbacks caused relative underperformance versus RTX. One thing that stands out is how institutional investors prioritized execution amid climbing military outlays, putting company risks ahead of sector positives.

Tools I Rely On: Tickeron’s AI Screener

In my research on stocks like LMT, I turn to Tickeron’s AI Screener to sift through the market efficiently. This AI-powered tool lets me filter thousands of stocks and ETFs using custom criteria like technical patterns, fundamentals, trends, volatility, and AI signals—such as industry peers, market cap, indicators, price patterns, and performance metrics. It surfaces trade ideas, breakouts, and opportunities faster than manual scans, which has been helpful for spotting setups in sectors like aerospace and defense.

What's Next for LMT Investors

I'm watching LMT's execution on F-16 and F-35 deliveries closely, as improvements there could steady the ship. Keep an eye on U.S. defense budget updates, geopolitical demand for missiles and aircraft, and supply chain progress in the sector. The reaffirmed 2026 guidance points to mid-single-digit sales growth and FCF rebound, with peers like RTX and Boeing offering context. Downside risks linger from more delays or overruns, but upside could come from new contracts and backlog work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: LMT

LMT sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for LMT moved below the 200-day moving average on September 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LMT as a result. In 42 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.

The Moving Average Convergence Divergence Histogram (MACD) for LMT turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 19 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 44%.

LMT moved below its 50-day moving average on September 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LMT crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 38%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.

The Aroon Indicator for LMT entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMT advanced for three days, in 204 of 348 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock slightly better than average.

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.643) is normal, around the industry mean (6.305). P/E Ratio (19.104) is within average values for comparable stocks, (58.116). Projected Growth (PEG Ratio) (0.978) is also within normal values, averaging (2.564). Dividend Yield (0.027) settles around the average of (0.009) among similar stocks. P/S Ratio (1.616) is also within normal values, averaging (18.330).

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. LMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.94B. The market cap for tickers in the group ranges from 4.49 to 1.92T. SPCX holds the highest valuation in this group at 1.92T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -11%. SPCX experienced the highest price growth at 18%, while PUSA experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 70
Price Growth Rating: 62
SMR Rating: 77
Profit Risk Rating: 76
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
LMT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of components and systems for aerospace and defense use

Industry AerospaceDefense

Industry
Aerospace And Defense
Address
6801 Rockledge Drive
Phone
+1 301 897-6000
Employees
123000
Web
https://www.lockheedmartin.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.
MU shares are declining approximately -6.00% in premarket trading on April 2, 2026, pulling back to roughly $353.70 from the prior session's close of $376.27. The primary catalyst is a sweeping new round of tariff announcements from the Trump administration, dubbed by markets as "Liberation Day 2.0," which has sparked a broad risk-off selloff across technology and semiconductor stocks